Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry

Leonardo De Luca1*, MD, PhD, FACC, FESC; Fabrizio D’Ascenzo2, MD; Giuseppe Musumeci3, MD; Francesco Saia4, MD; Guido Parodi5, MD; Ferdinando Varbella6, MD; Alfredo Marchese7, MD; Stefano De Servi8, MD, FESC; Sergio Berti9, MD; Leonardo Bolognese10, MD, FESC; on behalf of the SCOPE Investigators

1. Division of Cardiology, San Giovanni Evangelista Hospital, Tivoli, Rome, Italy; 2. Division of Cardiology, Department of Internal Medicine, Città della Salute e della Scienza, Turin, Italy; 3. USC Cardiologia, Ospedale Santa Croce e Carle, Cuneo, Italy

Aims: In patients with acute coronary syndromes (ACS) undergoing a percutaneous coronary intervention (PCI), switching of oral P2Y12 receptor inhibitors may fr

Sign in to read and download the full article

Login Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

adjunctive pharmacotherapymyocardial infarction

Coronary interventionsSTEMINSTEMIAdjunctive pharmacotherapyAdjunctive pharmacotherapy

Share on Facebook Share on Twitter Share on Linkedin

Read next article

Left ventricular function determines the survival benefit for women over men after transcatheter aortic valve implantation (TAVI)